Shkreli inflated price of life-saving drug from federal prison, FTC says
14-08-2020
Shkreli says he isn’t responsible for Daraprim ‘monopoly’
30-07-2020
Mark Van Scyoc / Shutterstock.com
The US Federal Trade Commission (FTC) should avoid reviewing communications between Martin Shkreli and his attorneys, but these are not protected under the Privacy Act, a New York federal judge has ruled.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
FTC, Federal Trade Commission, Privacy Act, Martin Shkreli, Vyera Pharmaceuticals, antitrust, Daraprim, monopoly, communications, attorney, BOP
